New OASAS Medical Advisory Panel (MAP) Xylazine Guidance
OASAS has posted the new OASAS Medical Advisory Panel (MAP) Xylazine Guidance document. Please share widely with your staff. Please…
May 1, 2023 by NYSAM
OASAS has posted the new OASAS Medical Advisory Panel (MAP) Xylazine Guidance document. Please share widely with your staff. Please…
April 26, 2023 by NYSAM
One year of pilot funding of up to $75,000 for research into chronic pain and opioid use disorder IMPOWR-ME is…
April 17, 2023 by NYSAM
Please join us for our upcoming General Membership Learning Session, scheduled for Monday, May 1st from 8-9PM. Pamela Mund, MD,…
March 30, 2023 by NYSAM
Join The Division on Addictions of the New York State Psychological Association (NYSPA) and the Concentration in Mental Health and…
March 30, 2023 by NYSAM
On March 29th, the the U.S. Food and Drug Administration (FDA) approved the first nonprescription, “over-the-counter” (OTC) naloxone nasal spray, Narcan. This…
January 30, 2023 by NYSAM
Join the Hazelden Betty Ford Graduate School for our virtual open house on Thursday, February 9. We will come together…